Developer docs
API playgroundTry for free, no card

Search company profiles

Molecular Discovery

Full company profile

uuid000pkp5

Namestring
Molecular Discovery
Legal namestring
Molecular Discovery Ltd.
Company typeenum
Private
Founded yearint
1984
Descriptiontext

Molecular Discovery Ltd. is a privately held UK-based computational chemistry and cheminformatics software company founded in 1984 and headquartered in Borehamwood, with its primary R&D and software development operations based in Perugia, Italy, and a training site in Sant Cugat del Vallès, Barcelona. The company's product portfolio is built on a single proprietary foundation, the GRID forcefield for Molecular Interaction Fields (MIFs), originally created by Peter Goodford and used in the discovery of Glaxo's anti-flu drug Relenza. Around this core engine, Molecular Discovery ships a suite of more than 15 software products spanning structure-based drug design (GRID, FLAP, SHOP), metabolism prediction (MetaSite/MetaSite 7, Mass-MetaSite), physicochemical and ADME modelling (MoKa, VolSurf+), bioisosteric fragment replacement (MetaDesign), metabolomics and lipidomics (MARS, Lipostar/Lipostar2), protein pocket comparison (BioGPS), forensic imaging (iFIS), and a unified web container platform (ONIRO), with WebMetabase serving as the metabolite database and design environment. The flagship MetaSite algorithm is training-set independent, claims approximately 85% accuracy in site-of-metabolism prediction and over 95% top-ranked success in Mass-MetaSite automated metabolite identification, while BioGPS provides a curated database of approximately 800,000 protein binding pockets.

The business model combines quote-based commercial software licensing (Solo single-user and Site-wide Unlimited Suite editions, with multi-year contracts), a less profitable Academic License tier, fee-based training courses priced at $250–$500 per person-day, a deliberately limited number of consulting agreements, and an annual Cytochrome P450 Consortium membership that gives participating pharmaceutical companies access to proprietary homogeneous human CYP metabolism data and predictive in silico models. Molecular Discovery's go-to-market is sales-led, with direct licensing to pharmaceutical, biotech, academic, and contract research users; channel distribution for MARS metabolomics through Mass Analytica; and OEM integrations via the Accelrys/BIOVIA Pipeline Pilot ISV Program and the Waters UNIFI platform. The customer base is anchored by a roster of top-tier pharmaceutical companies (AstraZeneca, Novartis, Pfizer, Merck, Roche, BMS, Vertex, Sanofi-Aventis, Servier, among others) and is supplemented by academic, food (Nestlé Research Center), GPCR-focused biotech (SoseiHeptares), and forensic/law enforcement users of iFIS.

Short descriptiontext

Molecular Discovery Ltd. provides proprietary GRID-based computational chemistry and cheminformatics software — including MetaSite, Mass-MetaSite, GRID, FLAP, MoKa, VolSurf+, and BioGPS — to pharmaceutical, biotech, academic, and forensic customers for drug design, ADME prediction, metabolite identification, and binding-site analysis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBorehamwood, United Kingdom
HQ citystring
Borehamwood
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational chemistry software, drug discovery software, metabolism prediction software, ADME prediction tools, metabolite identification software
Industry5 codes
PRIMARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAG
Metabolomics & Lipidomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Computational Chemistry / Drug Discovery Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Licensing
TypeSubscription Recurring
Description

Commercial software licenses sold directly to pharmaceutical companies and research institutions. All software products require login/registration to download. Academic licenses available with limited support. Site-wide unlimited license options (Suite editions) provide broader enterprise deployment.

moldiscovery.com
2Training Courses
TypeProfessional Services
Description

In-person and online training workshops on Molecular Discovery software and Drug Design methodologies. Training courses held at MD facilities (Perugia, Italy; Sant Cugat del Vallés, Barcelona, Spain) and at customer sites. Pricing at 250 USD/day or 500 USD for multi-day packages.

moldiscovery.com
3Consulting Agreements
TypeProfessional Services
Description

Consulting agreements in research areas related to chemometrics and drug discovery, potentially involving scientific software development with limited exclusive rights. MD accepts a very limited number of such collaborations annually.

moldiscovery.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details4 tiers
1Academic License
ModelSubscriptionBilling cadenceAnnual
Notes

Academic licenses are available with no user support, but academic users can access a users mailing list. Pricing not publicly disclosed.

moldiscovery.com
2Commercial License (Solo/Suite editions)
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Many products offered in Solo (single-user interactive interface) and Suite (unlimited site-wide access + command-line utilities) editions. Pricing not publicly disclosed — quote-based. Fax and private email support included in commercial license price.

moldiscovery.com
3Training Course Fee
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Training courses priced at 250 USD per person per day, or 500 USD per person for multi-day packages (e.g., 3-day course). Computer rental available at 100 USD/day. Lunch and coffee breaks included.

moldiscovery.com
4Cytochrome P450 Consortium Membership
ModelOtherBilling cadenceAnnual
Notes

Pharmaceutical companies join the consortium to gain access to high-quality homogeneous experimental data for human CYP metabolism and in silico models developed by MD. Contact Dr. Martin Bohl at Molecular Discovery for membership details.

moldiscovery.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Molecular Discovery sells computational chemistry and cheminformatics software used by pharmaceutical companies and academic researchers for drug discovery. The portfolio covers metabolism prediction (MetaSite), high-throughput metabolite identification from LC-MS/MS data (Mass-MetaSite), physicochemical property prediction (MoKa, VolSurf+), virtual screening and docking (FLAP, BioGPS), lipidomics and metabolomics (Lipostar, MARS), 3D-QSAR (Pentacle), scaffold hopping (SHOP), forensic fingermark imaging (iFIS), and the ONIRO web container platform. All products are built on the proprietary GRID forcefield that calculates Molecular Interaction Fields via 74 chemical probes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Reduces manual metabolite identification from several hours to minutes per compound (Mass-MetaSite)
+6 more records
Product overview1 text field

Molecular Discovery offers a comprehensive computational chemistry and cheminformatics software suite built on the proprietary GRID forcefield for Molecular Interaction Fields (MIFs). The portfolio includes MetaSite/MetaSite 7 as the flagship metabolism prediction platform (Phase I/II CYPs, FMO, AOX, and 40+ other enzymes), Mass-MetaSite for high-throughput automated metabolite identification from LC-MS/MS data, WebMetabase as a web-based metabolite database and design platform, ONIRO as the unified web container platform, and Mass-ChemSite for organic synthesis product elucidation. Structure-based design is supported by GRID (core MIF calculation engine with 74 probes), FLAP (virtual screening, docking, pharmacophore elucidation, WaterFLAP, FLAPdock), and BioGPS (protein pocket comparison with ~800,000 curated pockets). Physicochemical property prediction is handled by MoKa (pKa, logP/D, logS, tautomers, PROTAC mode) and VolSurf+ (128 ADME descriptors with built-in models). The lipidomics/metabolomics suite includes Lipostar 2 (LC-MS/MS lipidomics) and MARS (untargeted/semi-targeted metabolomics and exposomics). Additional tools include Pentacle (alignment-independent 3D QSAR), SHOP (scaffold hopping), iFIS (forensic fingermark imaging with AI grading), and MetaDesign (bioisosteric replacement). All products integrate with Pipeline Pilot via Accelrys ISV Program, and Mass-MetaSite connects to Waters UNIFI platform.

Product and service18 records
1GRID
CategoryStructure-Based Drug Design
Description

Computational procedure for determining energetically favourable binding sites on molecules of known structure through Molecular Interaction Fields (MIFs) using 74 chemical probe types. Foundation technology underlying all Molecular Discovery products including ADME prediction, site of metabolism prediction, virtual screening, pharmacophore elucidation, water prediction, and 3D-QSAR. Used by medicinal chemists and computational chemists for structure-based drug design.

2MetaSite / MetaSite 7
CategoryMetabolism Prediction
Description

Computational procedure predicting metabolic transformations related to cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO3) mediated reactions in Phase I metabolism, extended in version 7 to Phase II. Uses GRID Molecular Interaction Fields combined with chemical reactivity and reaction mechanism propensity; training-set independent with ~90% accuracy for top-3 predictions. Used by medicinal chemists and DMPK scientists during lead optimisation.

3Mass-MetaSite
CategoryMetabolite Identification
Description

High-throughput automatic metabolite identification software for small molecules and peptides using LC-MS/MS, UV, fluorescence, and radio-chromatogram data. Reduces manual analysis from hours to minutes per compound. Supports Waters, Agilent, Bruker, Sciex, and Thermo instruments with multiple acquisition modes (DDA, MSE, HDMSE, SWATH, SONAR, AIF). Integrates with the Waters UNIFI platform. Used by DMPK and metabolite identification scientists.

4FLAP
CategoryVirtual Screening and Docking
Description

Comprehensive virtual screening, docking, water prediction, pharmacophore elucidation, and 3D-QSAR software using GRID Molecular Interaction Fields. Provides ligand-ligand, ligand-receptor, and receptor-receptor comparison via pharmacophoric quadruplet fingerprints. Includes WaterFLAP for binding site water prediction and FLAPdock for structure-based pose prediction. Used by computational chemists and medicinal chemists for hit finding and lead optimisation.

5BioGPS
CategoryProtein Binding Site Analysis
Description

Protein binding site comparison software for drug repurposing, off-targeting prediction, and ligand selectivity. Uses GRID MIFs and pharmacophoric fingerprints for pocket-pocket virtual screening against a curated database of ~800,000 pockets with pre-computed MIFs and biological annotation. Supports the Runaway cloud service for large computations. Used by computational chemists and structural biologists.

6MoKa
CategoryPhysicochemical Property Prediction
Description

Physicochemical properties prediction software for pKa, logP, logD, logS0, tautomer enumeration/stability, and ionization states. Trained on 25,000+ pKa values with 0.4 log unit prediction error. Self-trainable with in-house experimental data. Includes PROTAC mode for Proteolysis Targeting Chimeras. Available in Solo (interactive GUI) and Suite (unlimited interface + command-line + training module) editions. Used by medicinal chemists and computational chemists.

7VolSurf+
CategoryADME / Pharmacokinetic Prediction
Description

ADME and pharmacokinetic modeling software calculating 128 molecular descriptors from GRID MIFs. Predicts passive intestinal absorption, blood-brain barrier permeation, solubility, protein binding, volume of distribution, and metabolic stability. Includes VolSurf+ Selector (virtual screening), Modeller (statistical modelling), and Designer (interactive optimisation). Available in Solo and Suite editions. Used by DMPK scientists and computational chemists.

8ONIRO
CategoryPlatform Infrastructure
Description

Web container platform encapsulating Molecular Discovery solutions for structure elucidation, in-silico predictions, spectral database, search, and reporting. Distributes WebMetabase, Compound Library, WebChembase, and WebQuant applications with unified user access, workgroup management, and licensing control. Used by enterprise customers requiring centralised deployment of MD's web applications.

9Mass-ChemSite
CategoryStructure Elucidation
Description

Software for structure elucidation of organic molecules from chemical reactions using High Resolution Mass Spectroscopy (HRMS). Applications include C-H functionalisation synthesis, forced degradation studies, agroscience, by-products identification, and targeted analysis. Covers small molecules and peptides up to 5,000 MW. Used by synthetic chemists and structure elucidation experts.

10Lipostar 2
CategoryLipidomics Software
Description

Comprehensive vendor-neutral software for LC-MS/MS-based lipidomics (DDA and DIA). Includes DB Manager for lipid database generation, spectral matching identification, oxidized species detection, gap-filler algorithm, multivariate statistical analysis, and lipid pathways. Supports Agilent, Waters, Thermo, Sciex, Bruker, and Shimadzu instruments. Used by lipidomics and metabolomics researchers in pharma and academia.

11MARS
CategoryMetabolomics Software
Description

Vendor-neutral desktop application for untargeted and semi-targeted LC-MS-based metabolomics and exposomics. Covers data conversion, peak detection, statistical analysis, automated MS/MS-based metabolite annotation, quantification, and biopathway analysis. Supports databases from HMDB, MassBank of North America, and Microbial Metabolites Database. Distributed exclusively through Mass Analytica. Used by metabolomics and exposomics researchers.

12Pentacle
Category3D QSAR Modeling
Description

Advanced alignment-independent 3D QSAR software calculating GRID Independent Descriptors (GRIND and GRIND2) from Molecular Interaction Fields. Automatically aligns structures using the CLACC algorithm for model interpretation. Builds and validates 3D QSAR models in minutes with multivariate analyses linked to 3D MIFs. Used by computational chemists and medicinal chemists for SAR analysis.

13SHOP
CategoryScaffold Hopping
Description

Scaffold hopping software guiding scaffold replacement during drug discovery. Uses client/server architecture with GRID forcefield interaction patterns and shape criteria to search scaffold databases for bioisosteric replacements considering synthetic feasibility and ADME profiles. Includes a sample combichem database. Used by medicinal chemists exploring chemical diversity and intellectual property space.

14iFIS
CategoryForensic Imaging Software
Description

Intelligent Fingermark Imaging System for mass spectrometry experts and law enforcement. Visualises fingermarks from a chemical perspective to improve biometric recognition and co-localise chemicals. Available in iFIS Ultra (for MS experts) and iFIS (for law enforcement). Features AI-based automated quality grading using Scotland Yard grades, image stitching, superimposition, and overlapping fingermark separation. Used by forensic labs and law enforcement agencies.

15WebMetabase
CategoryMetabolite Identification Database
Description

Web-based metabolite identification database, reviewing system, and design platform. Tracks metabolic schema, chromatograms, spectra, and fragmentation. Enables kinetic data analysis (half-life, clearance), matrix analysis (cytochrome reaction phenotyping), compound series analysis (SMRt), and design tools including MetaDesign via web interface. Distributed through ONIRO. Used by DMPK scientists for collaborative MetID workflows.

16Software Training Courses
CategoryTraining Services
Description

In-person and online training workshops covering Molecular Discovery software and drug design methodologies. Courses held at MD facilities (Perugia, Italy; Sant Cugat del Vallès, Barcelona, Spain) and at customer sites. Priced at 250 USD/person per day, 500 USD for multi-day packages (e.g., 3-day course), with optional computer rental at 100 USD/day. Lunch and coffee included.

17Research Consulting Agreements
CategoryConsulting Services
Description

Consulting agreements in chemometrics and drug discovery research areas, potentially involving scientific software development with limited exclusive rights. Molecular Discovery accepts a very limited number of such collaborations annually. Intended for pharmaceutical and academic clients needing bespoke cheminformatics work.

18Cytochrome P450 Consortium Membership
CategoryConsortium / Industry Collaboration
Description

Consortium-led data and in silico model initiative led by Molecular Discovery, generating large homogeneous experimental datasets for human CYP metabolism (metabolic rate, substrate likelihood, inhibitor classification, isoform selectivity, metabolic stability, sites of metabolism, metabolic pathway elucidation). Pharmaceutical members gain access to the proprietary dataset and consortium-developed predictive models; managed by Dr. Martin Bohl.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
1Molecular Horizon srl
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-12-14
Description

Molecular Horizon srl is a partner organisation of LightDyNAmics European Training Network and co-organised a training workshop with Molecular Discovery in December 2020 on Design, Development and Commercial Release of Computational Software for Pharmaceutical Research.

moldiscovery.com
2LightDyNAmics (European Commission)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-12-14
Description

LightDyNAmics is a multidisciplinary European Training Network funded by the European Commission under the Horizon Marie Sklodowska-Curie Action. Molecular Discovery Ltd and Molecular Horizon srl are partner organisations. MD staff participate in practical tutorials for early stage researchers (ESRs) within the project.

moldiscovery.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-08-06
Description

Mass-MetaSite 3.4 directly interacts with the UNIFI platform from Waters Corporation. This new version reads and processes data obtained from UNIFI including the non-targeted approach based on Ion Mobility acquisition mode, HDMSE. This collaboration between Molecular Discovery, Waters, and Lead Molecular Design produced one of the first commercial approaches for metabolite identification using a 3rd party API implemented in UNIFI.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-10-16
Description

AstraZeneca joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models. Seven pharmaceutical companies initially signed up. Consortium data and models are made available to all members.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-10-16
Description

Novartis joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-10-16
Description

Pfizer joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-10-16
Description

Sanofi-Aventis joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-10-16
Description

Servier joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-10-16
Description

Accelera joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.

10Solvay Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-10-16
Description

Solvay Pharmaceuticals joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.

moldiscovery.com
Strategic tierCoreTypeTechnology or Integration
Description

Through the Accelrys Independent Software Vendors (ISV) Program, Molecular Discovery provides a full set of Pipeline Pilot components for MoKa, MetaSite, and VolSurf+. This embeds MD's cheminformatics capabilities into Accelrys/BIOVIA Pipeline Pilot enterprise workflows.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

MARS (MetAbolomics ReSearch) software is distributed exclusively through Mass Analytica. Customers interested in MARS are directed to mass-analytica.com for download, evaluation, and purchase.

13Nestlé Research Center
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with BioGPS for ligand-protein binding screening across the full proteome to identify new molecular initiating events (MIEs) for food chemicals.

moldiscovery.com
14SoseiHeptares
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with BioGPS for building the GPCRome platform — a GPCR binding site platform for similarity assessments and screening/ligand repurposing efforts.

moldiscovery.com
Strategic tierMinorTypeOthers
Description

Molecular Discovery uses Google Analytics for web analytics and Google services for sending email. Google Analytics uses cookies to help analyze website usage. IP addresses are transmitted to and stored by Google on servers in the United States.

Strategic tierMinorTypeOthers
Description

MailChimp is used to send Molecular Discovery's newsletter to registered users who have opted in. Personal information (name, email address) may be shared with MailChimp for this purpose.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers17 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability25 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature14 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecular Discovery

Computational Chemistry / Drug Discovery Softwaremoldiscovery.com

Molecular Discovery Ltd. provides proprietary GRID-based computational chemistry and cheminformatics software — including MetaSite, Mass-MetaSite, GRID, FLAP, MoKa, VolSurf+, and BioGPS — to pharmaceutical, biotech, academic, and forensic customers for drug design, ADME prediction, metabolite identification, and binding-site analysis.

What Molecular Discovery does

Molecular Discovery Ltd. is a privately held UK-based computational chemistry and cheminformatics software company founded in 1984 and headquartered in Borehamwood, with its primary R&D and software development operations based in Perugia, Italy, and a training site in Sant Cugat del Vallès, Barcelona. The company's product portfolio is built on a single proprietary foundation, the GRID forcefield for Molecular Interaction Fields (MIFs), originally created by Peter Goodford and used in the discovery of Glaxo's anti-flu drug Relenza. Around this core engine, Molecular Discovery ships a suite of more than 15 software products spanning structure-based drug design (GRID, FLAP, SHOP), metabolism prediction (MetaSite/MetaSite 7, Mass-MetaSite), physicochemical and ADME modelling (MoKa, VolSurf+), bioisosteric fragment replacement (MetaDesign), metabolomics and lipidomics (MARS, Lipostar/Lipostar2), protein pocket comparison (BioGPS), forensic imaging (iFIS), and a unified web container platform (ONIRO), with WebMetabase serving as the metabolite database and design environment. The flagship MetaSite algorithm is training-set independent, claims approximately 85% accuracy in site-of-metabolism prediction and over 95% top-ranked success in Mass-MetaSite automated metabolite identification, while BioGPS provides a curated database of approximately 800,000 protein binding pockets.

The business model combines quote-based commercial software licensing (Solo single-user and Site-wide Unlimited Suite editions, with multi-year contracts), a less profitable Academic License tier, fee-based training courses priced at $250–$500 per person-day, a deliberately limited number of consulting agreements, and an annual Cytochrome P450 Consortium membership that gives participating pharmaceutical companies access to proprietary homogeneous human CYP metabolism data and predictive in silico models. Molecular Discovery's go-to-market is sales-led, with direct licensing to pharmaceutical, biotech, academic, and contract research users; channel distribution for MARS metabolomics through Mass Analytica; and OEM integrations via the Accelrys/BIOVIA Pipeline Pilot ISV Program and the Waters UNIFI platform. The customer base is anchored by a roster of top-tier pharmaceutical companies (AstraZeneca, Novartis, Pfizer, Merck, Roche, BMS, Vertex, Sanofi-Aventis, Servier, among others) and is supplemented by academic, food (Nestlé Research Center), GPCR-focused biotech (SoseiHeptares), and forensic/law enforcement users of iFIS.

Molecular Discovery firmographics

Firmographics
Name
Molecular Discovery
Legal name
Molecular Discovery Ltd.
Website
https://moldiscovery.com
Company type
Private
Founded year
1984
Operating status
Operating
Headcount range
1–10 employees
Short description
Molecular Discovery Ltd. provides proprietary GRID-based computational chemistry and cheminformatics software — including MetaSite, Mass-MetaSite, GRID, FLAP, MoKa, VolSurf+, and BioGPS — to pharmaceutical, biotech, academic, and forensic customers for drug design, ADME prediction, metabolite identification, and binding-site analysis.
Ownership category
akta.pro rank

Molecular Discovery industry classification

Industry
Product category
Computational Chemistry / Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAG
Metabolomics & Lipidomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)

Keywords

  • Computational chemistry software
  • Drug discovery software
  • Metabolism prediction software
  • ADME prediction tools
  • Metabolite identification software

Where Molecular Discovery is headquartered

Location

Headquarters

HQ city
Borehamwood
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Molecular Discovery business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Software Licensing: Commercial software licenses sold directly to pharmaceutical companies and research institutions. All software products require login/registration to download. Academic licenses available with limited support. Site-wide unlimited license options (Suite editions) provide broader enterprise deployment.
  2. Training Courses: In-person and online training workshops on Molecular Discovery software and Drug Design methodologies. Training courses held at MD facilities (Perugia, Italy; Sant Cugat del Vallés, Barcelona, Spain) and at customer sites. Pricing at 250 USD/day or 500 USD for multi-day packages.
  3. Consulting Agreements: Consulting agreements in research areas related to chemometrics and drug discovery, potentially involving scientific software development with limited exclusive rights. MD accepts a very limited number of such collaborations annually.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualAcademic License
One time/ perpetual licenseMulti-year contractCommercial License (Solo/Suite editions)
Unit PricingMulti-year contractTraining Course Fee
OtherAnnualCytochrome P450 Consortium Membership

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

Molecular Discovery product offering

Product offering

Core offering

Molecular Discovery sells computational chemistry and cheminformatics software used by pharmaceutical companies and academic researchers for drug discovery. The portfolio covers metabolism prediction (MetaSite), high-throughput metabolite identification from LC-MS/MS data (Mass-MetaSite), physicochemical property prediction (MoKa, VolSurf+), virtual screening and docking (FLAP, BioGPS), lipidomics and metabolomics (Lipostar, MARS), 3D-QSAR (Pentacle), scaffold hopping (SHOP), forensic fingermark imaging (iFIS), and the ONIRO web container platform. All products are built on the proprietary GRID forcefield that calculates Molecular Interaction Fields via 74 chemical probes.

Product overview

Molecular Discovery offers a comprehensive computational chemistry and cheminformatics software suite built on the proprietary GRID forcefield for Molecular Interaction Fields (MIFs). The portfolio includes MetaSite/MetaSite 7 as the flagship metabolism prediction platform (Phase I/II CYPs, FMO, AOX, and 40+ other enzymes), Mass-MetaSite for high-throughput automated metabolite identification from LC-MS/MS data, WebMetabase as a web-based metabolite database and design platform, ONIRO as the unified web container platform, and Mass-ChemSite for organic synthesis product elucidation. Structure-based design is supported by GRID (core MIF calculation engine with 74 probes), FLAP (virtual screening, docking, pharmacophore elucidation, WaterFLAP, FLAPdock), and BioGPS (protein pocket comparison with ~800,000 curated pockets). Physicochemical property prediction is handled by MoKa (pKa, logP/D, logS, tautomers, PROTAC mode) and VolSurf+ (128 ADME descriptors with built-in models). The lipidomics/metabolomics suite includes Lipostar 2 (LC-MS/MS lipidomics) and MARS (untargeted/semi-targeted metabolomics and exposomics). Additional tools include Pentacle (alignment-independent 3D QSAR), SHOP (scaffold hopping), iFIS (forensic fingermark imaging with AI grading), and MetaDesign (bioisosteric replacement). All products integrate with Pipeline Pilot via Accelrys ISV Program, and Mass-MetaSite connects to Waters UNIFI platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • GRID Computational procedure for determining energetically favourable binding sites on molecules of known structure through Molecular Interaction Fields (MIFs) using 74 chemical probe types. Foundation technology underlying all Molecular Discovery products including ADME prediction, site of metabolism prediction, virtual screening, pharmacophore elucidation, water prediction, and 3D-QSAR. Used by medicinal chemists and computational chemists for structure-based drug design.
  • MetaSite / MetaSite 7 Computational procedure predicting metabolic transformations related to cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO3) mediated reactions in Phase I metabolism, extended in version 7 to Phase II. Uses GRID Molecular Interaction Fields combined with chemical reactivity and reaction mechanism propensity; training-set independent with ~90% accuracy for top-3 predictions. Used by medicinal chemists and DMPK scientists during lead optimisation.
  • Mass-MetaSite High-throughput automatic metabolite identification software for small molecules and peptides using LC-MS/MS, UV, fluorescence, and radio-chromatogram data. Reduces manual analysis from hours to minutes per compound. Supports Waters, Agilent, Bruker, Sciex, and Thermo instruments with multiple acquisition modes (DDA, MSE, HDMSE, SWATH, SONAR, AIF). Integrates with the Waters UNIFI platform. Used by DMPK and metabolite identification scientists.
  • FLAP Comprehensive virtual screening, docking, water prediction, pharmacophore elucidation, and 3D-QSAR software using GRID Molecular Interaction Fields. Provides ligand-ligand, ligand-receptor, and receptor-receptor comparison via pharmacophoric quadruplet fingerprints. Includes WaterFLAP for binding site water prediction and FLAPdock for structure-based pose prediction. Used by computational chemists and medicinal chemists for hit finding and lead optimisation.
  • BioGPS Protein binding site comparison software for drug repurposing, off-targeting prediction, and ligand selectivity. Uses GRID MIFs and pharmacophoric fingerprints for pocket-pocket virtual screening against a curated database of ~800,000 pockets with pre-computed MIFs and biological annotation. Supports the Runaway cloud service for large computations. Used by computational chemists and structural biologists.
  • MoKa Physicochemical properties prediction software for pKa, logP, logD, logS0, tautomer enumeration/stability, and ionization states. Trained on 25,000+ pKa values with 0.4 log unit prediction error. Self-trainable with in-house experimental data. Includes PROTAC mode for Proteolysis Targeting Chimeras. Available in Solo (interactive GUI) and Suite (unlimited interface + command-line + training module) editions. Used by medicinal chemists and computational chemists.
  • VolSurf+ ADME and pharmacokinetic modeling software calculating 128 molecular descriptors from GRID MIFs. Predicts passive intestinal absorption, blood-brain barrier permeation, solubility, protein binding, volume of distribution, and metabolic stability. Includes VolSurf+ Selector (virtual screening), Modeller (statistical modelling), and Designer (interactive optimisation). Available in Solo and Suite editions. Used by DMPK scientists and computational chemists.
  • ONIRO Web container platform encapsulating Molecular Discovery solutions for structure elucidation, in-silico predictions, spectral database, search, and reporting. Distributes WebMetabase, Compound Library, WebChembase, and WebQuant applications with unified user access, workgroup management, and licensing control. Used by enterprise customers requiring centralised deployment of MD's web applications.
  • Mass-ChemSite Software for structure elucidation of organic molecules from chemical reactions using High Resolution Mass Spectroscopy (HRMS). Applications include C-H functionalisation synthesis, forced degradation studies, agroscience, by-products identification, and targeted analysis. Covers small molecules and peptides up to 5,000 MW. Used by synthetic chemists and structure elucidation experts.
  • Lipostar 2 Comprehensive vendor-neutral software for LC-MS/MS-based lipidomics (DDA and DIA). Includes DB Manager for lipid database generation, spectral matching identification, oxidized species detection, gap-filler algorithm, multivariate statistical analysis, and lipid pathways. Supports Agilent, Waters, Thermo, Sciex, Bruker, and Shimadzu instruments. Used by lipidomics and metabolomics researchers in pharma and academia.
  • MARS Vendor-neutral desktop application for untargeted and semi-targeted LC-MS-based metabolomics and exposomics. Covers data conversion, peak detection, statistical analysis, automated MS/MS-based metabolite annotation, quantification, and biopathway analysis. Supports databases from HMDB, MassBank of North America, and Microbial Metabolites Database. Distributed exclusively through Mass Analytica. Used by metabolomics and exposomics researchers.
  • Pentacle Advanced alignment-independent 3D QSAR software calculating GRID Independent Descriptors (GRIND and GRIND2) from Molecular Interaction Fields. Automatically aligns structures using the CLACC algorithm for model interpretation. Builds and validates 3D QSAR models in minutes with multivariate analyses linked to 3D MIFs. Used by computational chemists and medicinal chemists for SAR analysis.
  • SHOP Scaffold hopping software guiding scaffold replacement during drug discovery. Uses client/server architecture with GRID forcefield interaction patterns and shape criteria to search scaffold databases for bioisosteric replacements considering synthetic feasibility and ADME profiles. Includes a sample combichem database. Used by medicinal chemists exploring chemical diversity and intellectual property space.
  • iFIS Intelligent Fingermark Imaging System for mass spectrometry experts and law enforcement. Visualises fingermarks from a chemical perspective to improve biometric recognition and co-localise chemicals. Available in iFIS Ultra (for MS experts) and iFIS (for law enforcement). Features AI-based automated quality grading using Scotland Yard grades, image stitching, superimposition, and overlapping fingermark separation. Used by forensic labs and law enforcement agencies.
  • WebMetabase Web-based metabolite identification database, reviewing system, and design platform. Tracks metabolic schema, chromatograms, spectra, and fragmentation. Enables kinetic data analysis (half-life, clearance), matrix analysis (cytochrome reaction phenotyping), compound series analysis (SMRt), and design tools including MetaDesign via web interface. Distributed through ONIRO. Used by DMPK scientists for collaborative MetID workflows.
  • Software Training Courses In-person and online training workshops covering Molecular Discovery software and drug design methodologies. Courses held at MD facilities (Perugia, Italy; Sant Cugat del Vallès, Barcelona, Spain) and at customer sites. Priced at 250 USD/person per day, 500 USD for multi-day packages (e.g., 3-day course), with optional computer rental at 100 USD/day. Lunch and coffee included.
  • Research Consulting Agreements Consulting agreements in chemometrics and drug discovery research areas, potentially involving scientific software development with limited exclusive rights. Molecular Discovery accepts a very limited number of such collaborations annually. Intended for pharmaceutical and academic clients needing bespoke cheminformatics work.
  • Cytochrome P450 Consortium Membership Consortium-led data and in silico model initiative led by Molecular Discovery, generating large homogeneous experimental datasets for human CYP metabolism (metabolic rate, substrate likelihood, inhibitor classification, isoform selectivity, metabolic stability, sites of metabolism, metabolic pathway elucidation). Pharmaceutical members gain access to the proprietary dataset and consortium-developed predictive models; managed by Dr. Martin Bohl.

Quantifiable outcome

  • Reduces manual metabolite identification from several hours to minutes per compound (Mass-MetaSite)
  • +6 more outcomes

Companies that use Molecular Discovery

Customer profile

Named customers17 records

Segments4 records

Ideal customer profiles4 records

Molecular Discovery technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability25 records

Feature14 records

Molecular Discovery partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered minor and core.

  • Molecular Horizon srlminorStrategic or Co-development Partner · 14 December 2020Molecular Horizon srl is a partner organisation of LightDyNAmics European Training Network and co-organised a training workshop with Molecular Discovery in December 2020 on Design, Development and Commercial Release of Computational Software for Pharmaceutical Research.
  • LightDyNAmics (European Commission)minorStrategic or Co-development Partner · 14 December 2020LightDyNAmics is a multidisciplinary European Training Network funded by the European Commission under the Horizon Marie Sklodowska-Curie Action. Molecular Discovery Ltd and Molecular Horizon srl are partner organisations. MD staff participate in practical tutorials for early stage researchers (ESRs) within the project.
  • Waters CorporationcoreTechnology or Integration · 6 August 2018Mass-MetaSite 3.4 directly interacts with the UNIFI platform from Waters Corporation. This new version reads and processes data obtained from UNIFI including the non-targeted approach based on Ion Mobility acquisition mode, HDMSE. This collaboration between Molecular Discovery, Waters, and Lead Molecular Design produced one of the first commercial approaches for metabolite identification using a 3rd party API implemented in UNIFI.
  • AstraZenecacoreStrategic or Co-development Partner · 16 October 2008AstraZeneca joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models. Seven pharmaceutical companies initially signed up. Consortium data and models are made available to all members.
  • NovartiscoreStrategic or Co-development Partner · 16 October 2008Novartis joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.
  • PfizercoreStrategic or Co-development Partner · 16 October 2008Pfizer joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.
  • Sanofi-AventiscoreStrategic or Co-development Partner · 16 October 2008Sanofi-Aventis joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.
  • ServiercoreStrategic or Co-development Partner · 16 October 2008Servier joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.
  • AcceleracoreStrategic or Co-development Partner · 16 October 2008Accelera joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.
  • Solvay PharmaceuticalscoreStrategic or Co-development Partner · 16 October 2008Solvay Pharmaceuticals joined the Cytochrome P450 Consortium led by Molecular Discovery. The consortium generates comprehensive experimental data for human CYP metabolism and develops predictive in silico models.
  • Accelrys (BIOVIA)coreTechnology or IntegrationThrough the Accelrys Independent Software Vendors (ISV) Program, Molecular Discovery provides a full set of Pipeline Pilot components for MoKa, MetaSite, and VolSurf+. This embeds MD's cheminformatics capabilities into Accelrys/BIOVIA Pipeline Pilot enterprise workflows.
  • Mass AnalyticacoreChannel Partner/ Reseller/ DistributorMARS (MetAbolomics ReSearch) software is distributed exclusively through Mass Analytica. Customers interested in MARS are directed to mass-analytica.com for download, evaluation, and purchase.
  • Nestlé Research CenterminorStrategic or Co-development PartnerCollaboration with BioGPS for ligand-protein binding screening across the full proteome to identify new molecular initiating events (MIEs) for food chemicals.
  • SoseiHeptaresminorStrategic or Co-development PartnerCollaboration with BioGPS for building the GPCRome platform — a GPCR binding site platform for similarity assessments and screening/ligand repurposing efforts.
  • GoogleminorOthersMolecular Discovery uses Google Analytics for web analytics and Google services for sending email. Google Analytics uses cookies to help analyze website usage. IP addresses are transmitted to and stored by Google on servers in the United States.
  • MailChimp (Intuit)minorOthersMailChimp is used to send Molecular Discovery's newsletter to registered users who have opted in. Personal information (name, email address) may be shared with MailChimp for this purpose.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Molecular Discovery competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Molecular Discovery social profiles

Digital presence

Molecular Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecular Discovery leadership team

Management profile

Number of profiles

Profiles16 records

Molecular Discovery funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecular Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Discovery

What does Molecular Discovery do?

Molecular Discovery sells computational chemistry and cheminformatics software used by pharmaceutical companies and academic researchers for drug discovery. The portfolio covers metabolism prediction (MetaSite), high-throughput metabolite identification from LC-MS/MS data (Mass-MetaSite), physicochemical property prediction (MoKa, VolSurf+), virtual screening and docking (FLAP, BioGPS), lipidomics and metabolomics (Lipostar, MARS), 3D-QSAR (Pentacle), scaffold hopping (SHOP), forensic fingermark imaging (iFIS), and the ONIRO web container platform. All products are built on the proprietary GRID forcefield that calculates Molecular Interaction Fields via 74 chemical probes.

Is Molecular Discovery a public or private company?

Molecular Discovery is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Molecular Discovery founded?

Molecular Discovery was founded in 1984. It employs 1 to 10 people.

Where is Molecular Discovery based?

Molecular Discovery is headquartered in Borehamwood, United Kingdom, in the Europe region.

How does Molecular Discovery make money?

Three revenue lines are on record. Software Licensing is the primary driver. The others are training Courses and consulting Agreements.

Does Molecular Discovery have an API?

No public API is recorded for Molecular Discovery.

What industry is Molecular Discovery in?

Molecular Discovery's product category is Computational Chemistry / Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAE, Cheminformatics & Molecular Modeling / CADD, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales